147

rmaceutical preclinical pipeline. ompound Name Trademark Marine Organisma Plitidepsin DMXBA (GTS-21) PM00104 PM01183 CDX-011 Marizomib linosporamide A; NPI-0052) PM060184 Bryostatin SGN-75 ASG-5ME NA NA NA NA cyanobacterium Mollusk/ NA cyanobacterium Bacterium Sponge Bryozoan Mollusk/ Beta-lactone-gamma lactam Polyketide Macrolide Iactone Antibody drug conjugate (MM auristatin F) Antibody drug conjugate (MM auristatin E) 20S proteasome Minor groove of DNA Protein kinase C CD70 & microtubules ASG-5 & microtubules 4 1 38 2 2 Cancer Cancer Cancer Cancer Seattle Genetics Cancer maceutical pipeline consists of natural products, analogs or derivatives of compounds produced by this marine organism or a symbiont (e.g. cyanobacterium). otal trials as reported at http://www.clinicaltrials.gov/ in February 2013.148 Aplidin® NA Zalypsis® NA NA cyanobacterium Tunicate Worm Mollusk Tunicate Mollusk/ Chemical Class Depsipeptide Alkaloid Alkaloid Alkaloid Antibody drug conjugate (MM auristatin E) Molecular Target Rac1 & JNK activation α7 nicotinic acetylcholine receptor DNA-binding Minor groove of DNA Glycoprotein NMB & microtubules Clinical Trialsb 7 4 3 4 3 Disease Area Cancer Schizophrenia Cancer Cancer Cancer Company/ Institution Pharmamar UCHSC Pharmamar Pharmamar Celldex Therapeutics Sponsored by Triphase Research and Development I Corporation (India) Pharmamar National Cancer Institute Seattle Genetics cology.midwestern.edu/clinPipeline.htm Study in support of Impact Assessment work on Blue Biotechnology 121

148 Publizr Home